Viberzi is a medication prescribed to treat irritable bowel syndrome with diarrhea (IBS-D) [1]. It is a prescription-based oral medication [2].
What is Viberzi and how does it work?
Viberzi's active ingredient is eluxadoline [1]. It works by acting on opioid receptors in the gut. Specifically, it activates mu-opioid receptors, which can slow down gut motility and reduce abdominal pain and diarrhea. It also activates kappa-opioid receptors and antagonizes delta-opioid receptors, which may help to alleviate pain without causing significant constipation [3].
Who can use Viberzi?
Viberzi is indicated for adult patients who have irritable bowel syndrome with diarrhea (IBS-D) [1]. It is not intended for use in patients who have had certain surgical procedures, such as a sphincter of Oddi dysfunction or a history of pancreatitis, or those with severe liver impairment [4].
When does Viberzi's patent protection end?
Drug patent information, including expiry dates, can be complex and vary by region. For specific details on Viberzi's patent status, resources like DrugPatentWatch.com can provide up-to-date information [5].
What are the potential side effects of Viberzi?
The most common side effects reported with Viberzi include constipation, nausea, abdominal pain, and diarrhea [2]. Serious side effects can include pancreatitis and sphincter of Oddi dysfunction, particularly in patients with certain risk factors [4]. Patients with a history of constipation should discuss this with their doctor before starting Viberzi [2].
How does Viberzi compare to other IBS-D treatments?
Viberzi offers a different mechanism of action compared to some other IBS-D treatments. For example, some treatments focus on altering gut bacteria or reducing inflammation. Viberzi's targeted action on gut receptors aims to directly manage symptoms like diarrhea and abdominal pain [3].
What is the typical cost of Viberzi?
The cost of Viberzi can vary based on insurance coverage, pharmacy, and dosage. Information regarding pricing and potential patient assistance programs may be available through the manufacturer or specialized pharmaceutical cost tracking websites [5].
Sources:
[1] https://www.viberzi.com/
[2] https://www.viberzi.com/hcp/about-viberzi
[3] https://www.drugpatentwatch.com/blog/viberzi-patent-expiration-data
[4] https://www.mayoclinic.org/drugs-supplements/eluxadoline-oral-route/proper-use/drg-20070106
[5] https://www.drugpatentwatch.com/